Captopril inhibits calpain-mediated apoptosis of myocardial cells in diabetic rats and improves cardiac function

LI-YA DONG1*, LI-PING YAO1*, JING ZHAO2, KE-KE JIN3 and XIAO-XIAO QIU3

1Department of Cardiothoracic Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai 200092; 2Department of Pathophysiology, Anqing Medical College, Anqing, Anhui 246052; 3Department of Pathophysiology, Wenzhou Medical University, Wenzhou, Zhejiang 325000, P.R. China

Received October 14, 2017; Accepted March 12, 2018

DOI: 10.3892/mmr.2018.9192

Abstract. To explore the effects of captopril on calpain-mediated apoptosis of myocardial cells and cardiac function in diabetic rats, 30 adult male Sprague-Dawley rats were randomly divided into three groups: Negative control (NC group), untreated diabetic rats (DM group) and diabetic rats treated with captopril (Cap group). Diabetes was induced by streptozotocin injection. Captopril was intragastrically administered at a daily dose of 50 mg/kg for 12 weeks; the NC and DM groups received an equivalent volume of saline. After 12 weeks of treatment, left ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVDEP), maximal rate of left ventricular pressure increase (+dp/dtmax), maximal rate of left ventricular pressure decrease (-dp/dtmax) and left ventricular mass index (LVMI) were measured. The levels of calpain-1, calpain-2, B-cell lymphoma (Bcl)-2, Bcl-2 associated protein X (Bax) and total caspase-3 were detected in cardiac tissue by western blot analysis. The apoptotic index (AI) was assessed with a terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling assay. The ultrastructure of cardiac tissue was determined by transmission electron microscopy. Compared with the NC group, LVDEP and LVMI were increased, whereas LVSP, +dp/dtmax and -dp/dtmax were decreased in the DM group. In the Cap group, LVDEP and LVMI were decreased, whereas LVSP, +dp/dtmax and -dp/dtmax were increased compared with the DM group. Bcl-2 protein expression was decreased, whereas the levels of calpain-1, calpain-2, Bax and total caspase-3 protein were increased in the DM group, compared with the NC group. Cap treatment increased Bcl-2 protein expression and decreased calpain-1, calpain-2, Bax and total caspase-3 protein expression compared with the DM group. Additionally, the AI was increased in the DM group compared with the NC group, and decreased in the Cap group compared with the DM group. Furthermore, ultrastructural examination demonstrated that myocardial cell injury was reduced in the Cap group compared with the DM group. Therefore, captopril improved myocardial structure and ventricular function, by inhibiting calpain-1 and calpain-2 activation, increasing Bcl-2 expression, reducing Bax expression and subsequently inhibiting caspase-3-dependent apoptosis.

Introduction

Diabetic cardiomyopathy (DC) results in the development of cardiac microvascular lesions and myocardial structural disruption caused by metabolic disorder (1). DC is one of the most common diabetic complications and is pathologically characterized by the apoptosis and hypertrophy of myocardial cells, myocardial interstitial fibrosis and inflammation. DC may lead to heart failure, a major cause of death among patients with DM (2,3). However, the pathogenic mechanisms underlying the development of DC have not been fully elucidated.

Previous studies reported that cell apoptosis is involved in the occurrence and development of DC (4-6). Myocyte apoptosis caused by the long-term effects of high blood glucose comprises a cascade amplification reaction of caspase hydrolysate that is regulated as the genetic level; the B-cell lymphoma (Bcl) family and caspase-3 serve important roles in apoptosis (4). Calpain, a member of the caspase superfamily, is a calcium-activated neutral protease. The earliest known members of the calpain family, calpain-1 and calpain-2, are the most extensively studied (7). Under certain pathological conditions, particularly a high-calcium environment, calpains are critical factors in inducing cell hypertrophy and/or death (8).

Key words: calpain, diabetic cardiomyopathy, captopril, apoptosis
Additionally, previous studies have revealed that upregulation of calpains in myocardial cells can lead to cell apoptosis (9,10).

Angiotensin-converting enzyme inhibitors (ACEIs) can inhibit myocardial cell apoptosis in diabetic rats, significantly improve cardiac function and effectively reverse ventricular remodeling in DC (11,12). However, whether ACEI regulates calpain-mediated apoptosis of myocardial cells and affects cardiac function in patients with DM remains unknown. It has been reported that angiotensin 2 receptor density increases in type 2 diabetic patients, and activation of the renin-angiotensin-aldosterone system can improve left ventricular function in patients with type 2 DM (13). In the present study, the ACEI captopril was investigated in streptozotocin (STZ)-induced diabetic rats for its effects on the apoptosis of myocardial cells in DM, the expression of apoptotic proteins and left ventricular function.

Materials and methods

Ethical approval of the study protocol. The present study was approved by the Ethics Committee of Wenzhou Medical University (Wenzhou, China). All experimental procedures conformed to the guidelines for the Animal Care and Use Committee of Wenzhou Medical University (Wenzhou, China).

Reagents and instruments. Captopril was purchased as 25 mg tablets from Changzhou Pharmaceutical Factory Co., Ltd. (Changzhou, China). STZ and sodium citrate were obtained from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). The terminal deoxynucleotidyltransferase-mediated dUTP nick end labeling (TUNEL) assay kit was purchased from Wuhan Boster Biological Technology, Ltd. (Wuhan, China). Antibodies against calpain-1 and calpain-2 and GAPDH were purchased from Genetimes Technology, Inc. (Shanghai, China); rabbit anti-mouse Bcl-2, Bcl-2 associated protein X (Bax), caspase-3 polyclonal antibodies and horseradish peroxidase (HRP)-tagged goat anti-rabbit secondary antibodies were obtained from OriGene Technologies, Inc. (Beijing, China). A bicinchoninic acid (BCA) protein assay kit was obtained from Pierce (Thermo Fisher Scientific, Inc., Waltham, MA, USA). Polyvinylidene fluoride (PVDF) membranes were purchased from Bio-Rad Laboratories, Inc. (Hercules, CA, USA) and a BeyoECL Plus Western Blotting chemiluminescence kit was purchased from Beyotime Institute of Biotechnology (Shanghai, China). The Johnson Sure Step® blood glucose meter, with blood sampled from the tail vein. The at the end of week 12, left ventricular function was assessed using the BL-420E bio-functional experiment system. Following this, all animals were sacrificed, hearts were harvested and stored in an ice bath. The hearts and left ventricles were weighed. Subsequently, the left ventricular tissues were used for making paraffin sections (4-6 μm) and electron microscope specimens or stored immediately in -70°C for western blotting.

Left ventricular function and left ventricular mass index (LVMI). The animals were intraperitoneally anesthetized with 10% chloral hydrate (350 mg/kg). A tracheal cannula was inserted into the rats and connected to a DH-140B animal ventilator; the tidal volume was 5 ml and the respiratory rate was 55 breaths per minute, with an inspiration/expiration ratio of 1.5:1. A cardiac catheter was subsequently inserted into the left ventricle to determine the left ventricular systolic pressure (LVSP), left ventricular end-diastolic pressure (LVDEP), maximal rate of left ventricular pressure increase (+dp/dtmax) and maximal rate of left ventricular pressure decrease (-dp/dtmax). Following this, rats were sacrificed to harvest the heart and the left ventricle was isolated. The mass of the left ventricle was measured. The LVMI was calculated as the mass of the left ventricle/mass of the heart.

Western blot analysis. The expression of calpain-1, calpain-2, Bcl-2, Bax and caspase-3 was examined by western blotting. Briefly, total protein of the heart tissue was extracted with Ultra-Lum, Inc. (Claremont, CA, USA); the H-600 transmission electron microscope (TEM) was obtained from Hitachi, Ltd. (Tokyo, Japan); and the light microscope was obtained from Olympus Corporation (Tokyo, Japan).
blocked in 5% non-fat dry milk for 1 h at room temperature and subsequently incubated overnight at 4°C with calpain-1 large-subunit antibody (1:400), calpain-2 large-subunit antibody (1:400), rabbit anti-mouse Bcl-2 (1:250), Bax polyclonal antibody (1:400) and caspase-3 polyclonal antibody (1:600). The membrane was rinsed in Tris-buffered saline with 0.05% Tween 20 prior to incubation with HRP-labeled secondary antibody (1:5,000; cat. no. 111-035-006) at room temperature for 2 h. Protein bands were visualized with the BeyoECL Plus Western Blotting chemiluminescence kit and analyzed with Quantity One software (version 4.52, Bio-Rad Laboratories, Inc.). GAPDH (1:1,000; cat. no. 5174) was included in as an internal reference for the quantification of relative protein expression.

Myocardial apoptosis and apoptotic index (AI). Apoptotic myocardial cells were detected by a TUNEL assay kit according to the manufacturer’s instructions (Wuhan Boster Biological Technology, Ltd.). Paraffin sections of the heart tissues were dewaxed, rinsed in water and PBS, and treated with protease K solution at 37°C for 15 min. Tagging buffer (20 µl) was added at 37°C. After 60 min, samples were rinsed with PBS, stained with 0.05% 3,3′-Diaminobenzidine for 10 min at room temperature and counterstained with 0.025% hematoxylin for 1 min at room temperature. Positive cells (apoptotic) were characterized by brown granules inside the nucleus. Apoptotic cells in five random high-power visual fields (magnification, x400) were counted under a light microscope. AI (%) was determined as the apoptotic cell count/100 cells (15).

Myocardial ultrastructure observation. Myocardial tissue (1x1x1 mm³) was collected from the anterior wall of the left ventricle, pre-fixed in 2.5% glutaraldehyde and post-fixed in 1% osmic acid at 37°C for 60 min. Samples were subsequently dehydrated with a gradient of acetone (50% acetone for 10 min, 70% acetone for 10 min, 80% acetone for 10 min, 90% acetone for 10 min and twice with 100% acetone for 10 min), embedded in Epon812 (45°C for 6 h then 65°C for 48 h) and sliced into ultrathin sections (1 µm). Samples were double stained with 4% lead nitrate for 10 min at room temperature and uranyl acetate 30 min at room temperature and observed by TEM.

Statistical analysis. SPSS 17.0 software (SPSS, Inc., Chicago, IL, USA) was used to perform the statistical analyses. All data are expressed as the mean ± standard deviation. The data in each group were subjected to normality testing and homogeneity of variance was analyzed. Inter-group comparisons were performed by one-way analysis of variance. Pairwise comparisons between groups with homogeneous variance were performed with LSD method, whereas comparisons
between groups with homogeneous variance were performed with Dunnett’s T3 test. P<0.05 was considered to indicate a statistically significant difference.

Results

Captopril treatment increases body weight and reduces glucose levels in diabetic rats. Compared with the DM group, animals in the Cap group exhibited significant improvement in DM-associated symptoms, including polydipsia, polyphagia and polyuria. Cap rats were relatively active and their coats regained luster. The body weights in the DM and Cap groups were significantly decreased compared with those in the NC group. Furthermore, the body weights in the Cap group were significantly increased compared with the DM group (P<0.05; Fig. 1A). Blood glucose at 12 weeks was significantly increased in the DM and Cap groups, compared with the NC group (P<0.05). Cap group glucose levels were significantly decreased compared with those in the DM group (P<0.05; Fig. 1B).

Captopril treatment improves cardiac function in diabetic rats. Compared with the NC group, DM rats had significantly increased LVDEP and LVMI. LVSP, +dp/dtmax and -dp/dtmax were significantly decreased in the DM group, compared with the NC group. Furthermore, compared with the DM group, Cap-treated rats had significantly lower LVDEP and LVMI. LVSP, +dp/dtmax and -dp/dtmax significantly increased compared with the DM group (P<0.05; Table I).

Captopril reduces cell apoptosis in myocardial tissue. In the NC group, cell apoptosis was rarely observed. Compared with the NC group, apoptosis in the DM group increased by ~15-fold (P<0.05). Captopril treatment decreased the number of apoptotic cells by 24%, compared with the DM group (P<0.05; Fig. 2).

Calpain-1, calpain-2, Bcl-2, Bax and total caspase-3 expression alterations in heart tissue in response to captopril. Compared with the NC group, Bcl-2 expression was significantly decreased in the DM group, while calpain-1, calpain-2, Bcl-2, Bax and total caspase-3 expression significantly increased (P<0.05). By contrast, captopril treatment significantly increased Bcl-2 expression and significantly reduced calpain-1, calpain-2, Bax and total caspase-3 expression compared with the DM group (P<0.05; Fig. 3).

Alterations in myocardial ultrastructure in response to captopril. The myocardium of rats in the NC group exhibited solid myofibrils and regularly distributed myofilaments. The mitochondrial membranes were intact and the arrangement of the ridges was regular. The basilar membranes of the microvessels were continuous and intact (Fig. 4A). In the myocardium of the DM group, the myocytes were swollen and punctiform myofibril dissolution was observed. The arrangement of the myofilaments was irregular and myofilaments were partially disrupted. The mitochondria were enlarged and the ridge arrangement was disrupted, with the presence of vacuoles. Interstitial collagen hyperplasia was observed and the basement membranes of the microvessels were thickened (Fig. 4B).

In the Cap group, the myofibrils were partially disrupted. Mitochondrial enlargement was alleviated. Minor disruptions were observed in the ridges and the basement membrane thickening of the microvessels was attenuated (Fig. 4C).

Table I. Comparison of cardiac function among different groups in rats.

<table>
<thead>
<tr>
<th>Group</th>
<th>LVSP (mmHg)</th>
<th>LVDEP (mmHg)</th>
<th>+dp/dtmax (mmHg/s)</th>
<th>-dp/dtmax (mmHg/s)</th>
<th>LVMI (mg/g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NC</td>
<td>118.20±10.83</td>
<td>3.57±1.19</td>
<td>5.382.43±693.10</td>
<td>5.310.53±696.23</td>
<td>1.53±0.16</td>
</tr>
<tr>
<td>DM</td>
<td>90.20±8.87*</td>
<td>10.80±3.37*</td>
<td>3.783.52±863.27*</td>
<td>3.725.95±864.76*</td>
<td>2.25±0.30*</td>
</tr>
<tr>
<td>Cap</td>
<td>103.41±9.36*</td>
<td>5.10±1.21*</td>
<td>47.89.99±707.06*</td>
<td>5.024.43±573.60*</td>
<td>1.82±0.21*</td>
</tr>
</tbody>
</table>

*P<0.05 vs. NC group, *P<0.05 vs. DM group. NC, negative control; DM, diabetes mellitus; Cap, captopril; LVSP, left ventricular systolic pressure; LVDEP, left ventricular end-diastolic pressure; +dp/dtmax, maximal rise rate of left ventricular pressure; -dp/dtmax, maximal fall rate of left ventricular pressure; LVMI, left ventricular mass index. Data are presented as the mean ± standard deviation.
In the present study, it was demonstrated that treatment with captopril increased body weight and reduced blood glucose in diabetic rats. This result was consistent with a previous study reporting that captopril can protect islet function, prevent diabetes occurrence and improve diabetic rat weight loss (16, 17). In the present study, captopril improved cardiac function, inhibited myocardial cell apoptosis and protected myocardial structure, thereby improving ventricular function. This was likely achieved by reducing the activation of calpain-1, calpain-2 and Bax, as well as upregulating the expression of Bcl-2, leading to the inhibition of caspase-3-dependent apoptosis.

At week 12, STZ-induced diabetic rats in the current study exhibited abnormalities in the systole and diastole of the left ventricle and structural damage in the myocardium, including a significant increase in myocardial cell apoptosis. This was consistent with a previous study demonstrating that left ventricular systolic and diastolic dysfunction in DC is associated with myocardial cell apoptosis (18). The mechanism underlying the diabetes-induced apoptosis of myocytes is complex, involving the Bcl-2 and caspase gene families (19, 20). Bcl-2 was the first anti-apoptotic gene discovered in humans (21). Although Bax is also a member of the Bcl-2 family, it functions as a pro-apoptotic gene. High Bcl-2 expression may lead to the formation of Bcl-2/Bcl-2 homodimers and Bcl-2/Bax heterodimers, both of which have anti-apoptotic effects; however, high expression of Bax may yield Bax/Bax homodimers, which are pro-apoptotic (21). Whether apoptosis occurs in a certain group of cells and how much they are affected is determined...
by the ratio of Bcl-2 and Bax expression (22). In the present study, it was demonstrated that Bcl-2 was significantly decreased and Bax significantly increased in the DM group, compared with the NC group. This is in accordance with the results reported by Kumar et al. (23), which revealed that the number of apoptotic myocardial cells increases in DM, along with a decrease in Bcl-2 expression and increase in Bax expression.

The caspase family is a group of proteins critical for regulating and executing cell apoptosis. Caspase-3 is referred to as the 'death protease', as its activated form catalyzes the hydrolysis of specific proteins to promote apoptosis (24,25).

In the present study, apoptosis induced by hyperglycemia is regulated by the caspase-3-dependent mitochondrial pathway. Cai et al. (26) demonstrated that high glucose-induced cell apoptosis occurs at least partially via a caspase-3-dependent mitochondrial pathway.

Calpains are a family of calcium-dependent cysteine proteases in the cytoplasm that are distributed widely in most mammals. Calpain-1 and calpain-2 are the most extensively studied members of this family; both are heterodimers composed of 28 and 80 kDa subunits and may be expressed in myocytes. Their sequences share 55-65% homology. Calpain-1 and -2 differ in that they require different calcium concentrations for their activation; μmol levels for calpain-1 and mmol levels for calpain-2. Typically, Ca\(^{2+}\) concentration in myocytes is not sufficient to activate these calpains (27). However, high glucose may increase the calcium load in myocytes, which is associated with a decrease in the activity of the Na\(^{+}/Ca\(^{2+}\) exchanger ATPase and the Ca\(^{2+}\)-ATPase, and subsequently inhibits the calcium concentration resurge in the sarcoplasmic reticulum (28). As revealed by a previous report (27), high glucose may lead to the production of reactive oxygen species, causing the activation of L-type calcium channels and ryanodine receptors and increase of intracellular calcium concentrations, which subsequently leads to the activation of calpain. Activated calpain mediates the apoptosis of myocytes under high-glucose conditions via the caspase-3 pathway. An in vitro experiment demonstrated that pro-apoptotic Bax maybe cleaved by calpain to yield an 18 kDa active fragment, which induces the release of mitochondrial cytochrome c to mediate cell apoptosis (29). Therefore, the Bcl-2 family is involved in the pro-apoptotic effects of calpain, and several members of the Bcl-2 family are substrates of calpain (30).

In the present research, compared with the control group, Bcl-2 expression was downregulated in myocardial tissue, whereas calpain-1, calpain-2, Bax and total caspase-3 expression was increased in the DM group, indicating that cell apoptosis in DC may be associated with the alterations in the expression of these proteins. This is consistent with previous reports (21-23). Furthermore, activation of calpain-1 and calpain-2 may mediate caspase-3-dependent apoptosis by downregulating Bcl-2 and upregulating Bax to further induce the occurrence of DC.

ACEIs, including captopril, are considered protective agents against pancreatic dysfunction and diabetes (16). In the present study, captopril treatment alleviated the symptoms of DM rats. Local overactivation of the renin/angiotensin system (RAS) and dysfunction of angiotensin II (Ang II) are thought to be involved in DC apoptosis (31). Captopril may inhibit cell apoptosis by blocking local or systemic activation of RAS and inhibiting the bio-synthesis of Ang II (32). In the present study, increased expression of Bcl-2 and decreased expression of calpain-1, calpain-2, Bax and caspase-3 were observed in the myocardial tissue. Additionally, cell apoptosis was significantly inhibited, LVMI was decreased and systolic function was significantly improved. Furthermore, the ultrastructural damage in the myocardium was alleviated, suggesting that captopril may improve ventricular function and protect the myocardium by inhibiting the activation of calpain-1 and calpain-2, upregulating Bcl-2 and downregulating Bax to inhibit caspase-3-dependent myocyte apoptosis. A previous study reported similar functions of ACEI and calcium antagonists (33), both of which can ameliorate calcium overload. Therefore, ACEIs may inhibit calpain activation through the attenuation of calcium overload. However, further confirmation of this hypothesis is required.

In conclusion, the present study demonstrated that captopril may preserve myocardial function in diabetic rats via inhibition of cardiac cell apoptosis, suggesting that ACEIs, including captopril, maybe considered as a therapeutic option in DC.

**Acknowledgements**

We thank Professor Jianmin Li, a pathological specialist from Wenzhou Medical University (Wenzhou, China) for technical assistance in this study. We are deeply grateful to Fanyan Wang and Lei Ying, Pathophysiological doctors from Wenzhou Medical University for their kind assistance in proofreading the manuscript.

**Funding**

This investigation was supported by a grant from National Nature Science Foundation of China (grant no. 81170204) and College Students' Science and Technology Innovation Foundation of Zhejiang Province (grant no. 2010R413002).

**Availability of data and materials**

The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

**Author’s contributions**

LYD, LPY and XXQ designed the study, drafted the manuscript and approved its final version. JZ acquired data and revised the article for important intellectual content. KKJ was involved in generating the idea and gave final approval of the version to be published. All authors read and approved the final manuscript.

**Ethics approval and consent to participate**

The present study was approved by the Ethics Committee of Wenzhou Medical University. All experimental procedures conformed to the guidelines for the Animal Care and Use Committee of Wenzhou Medical University.
Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References